Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
UNKNOWN
Clinical Phase
NA
Total Enrollment
60 participants
Study Classification
INTERVENTIONAL
Study Start Date
2022-05-23
Study Completion Date
2024-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
There is a paucity of evidence-supported treatment choices for bipolar II depression (BD-II depression), hindered by multiple comorbidity and manic switch. In addition, a slower response also burdens the patients. Intermittent theta-burst stimulation (iTBS) is a new form of Repetitive transcranial magnetic stimulation (rTMS) which is more powerful and requires less time of operation (i.e., about 1/3 of traditional treatment time) compared to traditional rTMS protocols. The antidepressant effect of iTBS for major depressive disorder is well established; however, its effect for BD-II depression is still undetermined with few investigations. In the current study, the investigators plan to conduct a randomized, controlled study to directly compare antidepressant effects of iTBS (n=30) versus sham (n=30) for BD-II depression under treatment of quetiapine monotherapy. The participants will receive 10 times of iTBS sessions in 2 weeks (daily from Monday to Friday and off on the weekends for 2 weeks), followed on the end of week 2 (right after treatment,), week 6 and week 12. The investigators hypothesize that iTBS is effective for BD-II depression and may improve cognitive decline associated with BD-II. In addition, the investigators have identified several microRNAs (miRNAs) (miR-7-5p, miR-142-3p, miR-221-5p, and miR-370-3p) which may aid the diagnosis of BD-II and such diagnostic model was patented in Taiwan. The investigators further found significant correlations with these miRNAs with peripheral levels of brain derived neurotrophic factor (BDNF). The investigators inferred that these miRNAs may be associated with susceptibility with BD-II thru modulation of BDNF. Because modulation of BDNF level is one of the anti-depression mechanism for rTMS, the investigators plan to monitor the changes of these candidate miRNAs and BDNF levels in serum before and after iTBS treatment (week 0, 2,6,12), in attempt to clarify whether these miRNAs may be treatment biomarker as well. The investigators believe that the current study result may be a great addition for predictor for therapeutic assessment and precision treatment of BD-II depression.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Treatment for Major Depressive Disorder With Intermittent Theta-burst Stimulation
NCT05390593
Depressive Disorder, Treatment-Resistant
UNKNOWN
NA
Effect of Intermittent ThetaBurst Stimulation in Treatment-resistant Bipolar Depression
NCT02740244
Bipolar Depression
TERMINATED
NA
Intermittent Theta Burst Stimulation (iTBS) for Emotion Regulation in Bipolar Disorder
NCT06274567
Bipolar Disorder
RECRUITING
NA
Accelerated Intermittent Theta-Burst Stimulation Ameliorate Major Depressive Disorder by Regulating CAMKII Pathway
NCT05913960
Major Depressive Disorder
Major Depressive Disorder, Recurrent
RECRUITING
NA
Intensive TMS for Bipolar Depression
NCT05228457
Bipolar Depression
Treatment Resistant Depression
COMPLETED
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
In this 2-year prospective, randomized, and controlled study, the investigators plan to recruit a total of 60 patients with BD-II depression. According to a random distribution table, the participants will be randomly divided into the two subgroups, respectively: the real iTBS group (n=30) and the sham iTBS group (n=30). Patients with BD-II depression between 20 and 65 years old will be recruited in 2 years. Patients will be evaluated by research psychiatrists after a thorough medical and neurological workup. The Chinese Version of Modified Schedule of Affective Disorder and Schizophrenia-Life Time (SADS-L) will be conducted for confirmation of the diagnosis. Although DSM-IV-TR criteria require a minimum duration of 4 days of hypomania, current epidemiologic data suggest that a 2-day duration is more prevalent in community samples; therefore, the investigators will use the 2-day minimum for hypomania in the diagnosis of BD-II. Eligible participants, aged 20-65, need to have a DSM-IV-TR diagnosis of BD-II. HDRS and YMRS will be used to evaluate severity of mood symptoms. Only patients in depressive state (HDRS≧18) will be recruited. Inclusion criteria are those with diagnosis of BD-II either first-onset or with previous episodes. Exclusion criteria are (i) any DSM-IV-TR Axis I diagnosis, including organic mental disorders, substance use disorder, and other major and minor mental illnesses other than BD-II, (ii) any significant medical illness, (iii) any neurological disorders, and (iv) any poorly controlled physical illness that might influence the interview and study results; (v) any form of metal implants; (iv) any history of seizures, or medications known to lower seizure threshold; (vii) history of exposure to rTMS or electroconvulsive therapy.
During the course of the follow-up, all patients will receive open-label quetiapine adjusted individually according to the clinical response and side effects in the first two weeks and will be maintained till the end of the trial, with the final dose ranging from 200 to 700 mg/d. Concomitant benzodiazepine medication (lorazepam \< 4 mg) may be used for insomnia during the study. No other antidepressants, mood stabilizers, first or second-generation antipsychotics will be allowed during the study.
Twenty milliliters of whole blood will be withdrawn from the antecubital vein of each participant and prepared as serum for the purpose of total RNA extraction and for level of BDNF analysis.
The patients will be followed for 12 weeks and blood samples (20cc whole blood) and clinical symptoms will be examined at week0, the end of week 2, 6 and week 12.
Clinical severity will be assessed by the HDRS and YMRS and Clinical ratings will be performed by research psychiatrists who are trained and experienced in the rating scales. Assessments will be performed after recruitment, week 0 and on the end of week 2, 6, and 12. RNA extraction Serum will be isolated from the whole blood and stored at -80°C immediately.
The miRNeasy kit (Qiagen, CA) will be implemented for total RNA extraction using serum from all patients and controls.
Total RNAs will be isolated from 250-µL serum of clinical samples and subjected to quantitative detection of miRNA by using the cDNA TaqMan Advanced miRNA cDNA synthesis kit (Applied Biosystems, Inc., USA). Synthesized cDNA samples will then be subjected to qRT-PCR by using the TaqManR Universal PCR Master Mix II and TaqMan Advanced miRNA assays according to manufacturer's instructions (Applied Biosystems). Expression levels of miRNAs in serum will be normalized with miR-16. The following IDs of miRNA will be used: hsa-miR-7-5p (483061\_mir), hsa-miR-142-3p (477910\_mir), hsa-miR-370-3p (478326\_mir), and hsa-miR-221-5p (478778\_mir), and has-miR-16 (481312\_mir).
The level of plasma BDNF will be measured by a BDNF kit (Quantikine Human BDNF kit; R\&D Systems, Minneapolis, MN) and an enzyme-linked immunosorbent assay (ELISA) reader (SpectraMax-M2; Molecular Devices, Sunnyvale, CA) which has a minimum detectable dose of 80 pg/ml.
All iTBS procedures will be conducted in the Department of Psychiatry in Kaohsiung Veterans General Hospital. An Magstim Rapid2 stimulator with eight-figure coil was used for stimulation. The resting motor threshold (MT) will be determined by the minimum intensity of magnetic stimulation on the primary motor cortex to elicit five visible muscle contractions out of ten consecutive stimuli in the contralateral abductor pollicis brevis muscle . Because a recent meta-analysis found that low stimulation intensities, high number of pulses per session, short treatment periods (less or equal to 2 weeks), and intermittent TBS (iTBS) might be the optimal parameters of TBS protocols, investigators adopted the iTBS protocol which follows the standard TBS protocols, with 3-pulse 50-Hz bursts given every 200 ms (at 5 Hz) and an intensity of 80% motor threshold. In each session, a 2-s train of bursts will be repeated every 10 s for a total of 570 s (1800 pulses) to the left dorsolateral prefrontal cortex (DLPFC). TBS sessions will be scheduled daily in a 5-day sequence, for a total of 10 sessions in 2 weeks. The figure-eight coil will be positioned in a para-sagittal plane 5.5 cm anterior to the site of MT determination and magnetic stimulation will be consequently delivered to the brain region of left DLPFC. Finally, after the 2-week double-blind phase of active or sham iTBS treatment, each patient will be followed at week 6 and week 12 to evaluate the response to the iTBS treatment.
Neuropsychological function assessment Brief Assessment of Cognition in Affective Disorders (BACA) Investigators will adopt the BACA to evaluate objective cognitive functioning in patients with mood disorders. This instrument consists of seven subtests, including Verbal Memory (List Learning), Working Memory (Digit Sequencing), Processing Speed (Verbal Fluency; Token Motor Task; Symbol Coding), Reasoning and Problem Solving (Tower of London \[TOL\]), and tests of affective interference (emotional distractibility and affective memory) and emotional disinhibition, which are then summed up as affective composite scores. This assessment takes approximately 45 minutes.
During the course of the follow-up, all patients will receive open-label quetiapine adjusted individually according to the clinical response and side effects in the first two weeks and will be maintained till the end of the trial, with the final dose ranging from 200 to 700 mg/d. Concomitant benzodiazepine medication (lorazepam \< 4 mg) may be used for insomnia during the study. No other antidepressants, mood stabilizers, first or second-generation antipsychotics will be allowed during the study.
Twenty milliliters of whole blood will be withdrawn from the antecubital vein of each participant and prepared as serum for the purpose of total RNA extraction and for level of BDNF analysis.
The patients will be followed for 12 weeks and blood samples (20cc whole blood) and clinical symptoms will be examined at week0, the end of week 2, 6 and week 12.
Clinical severity will be assessed by the HDRS and YMRS and Clinical ratings will be performed by research psychiatrists who are trained and experienced in the rating scales. Assessments will be performed after recruitment, week 0 and on the end of week 2, 6, and 12. RNA extraction Serum will be isolated from the whole blood and stored at -80°C immediately.
The miRNeasy kit (Qiagen, CA) will be implemented for total RNA extraction using serum from all patients and controls.
Total RNAs will be isolated from 250-µL serum of clinical samples and subjected to quantitative detection of miRNA by using the cDNA TaqMan Advanced miRNA cDNA synthesis kit (Applied Biosystems, Inc., USA). Synthesized cDNA samples will then be subjected to qRT-PCR by using the TaqManR Universal PCR Master Mix II and TaqMan Advanced miRNA assays according to manufacturer's instructions (Applied Biosystems). Expression levels of miRNAs in serum will be normalized with miR-16. The following IDs of miRNA will be used: hsa-miR-7-5p (483061\_mir), hsa-miR-142-3p (477910\_mir), hsa-miR-370-3p (478326\_mir), and hsa-miR-221-5p (478778\_mir), and has-miR-16 (481312\_mir).
The level of plasma BDNF will be measured by a BDNF kit (Quantikine Human BDNF kit; R\&D Systems, Minneapolis, MN) and an enzyme-linked immunosorbent assay (ELISA) reader (SpectraMax-M2; Molecular Devices, Sunnyvale, CA) which has a minimum detectable dose of 80 pg/ml.
All iTBS procedures will be conducted in the Department of Psychiatry in Kaohsiung Veterans General Hospital. An Magstim Rapid2 stimulator with eight-figure coil was used for stimulation. The resting motor threshold (MT) will be determined by the minimum intensity of magnetic stimulation on the primary motor cortex to elicit five visible muscle contractions out of ten consecutive stimuli in the contralateral abductor pollicis brevis muscle . Because a recent meta-analysis found that low stimulation intensities, high number of pulses per session, short treatment periods (less or equal to 2 weeks), and intermittent TBS (iTBS) might be the optimal parameters of TBS protocols, investigators adopted the iTBS protocol which follows the standard TBS protocols, with 3-pulse 50-Hz bursts given every 200 ms (at 5 Hz) and an intensity of 80% motor threshold. In each session, a 2-s train of bursts will be repeated every 10 s for a total of 570 s (1800 pulses) to the left dorsolateral prefrontal cortex (DLPFC). TBS sessions will be scheduled daily in a 5-day sequence, for a total of 10 sessions in 2 weeks. The figure-eight coil will be positioned in a para-sagittal plane 5.5 cm anterior to the site of MT determination and magnetic stimulation will be consequently delivered to the brain region of left DLPFC. Finally, after the 2-week double-blind phase of active or sham iTBS treatment, each patient will be followed at week 6 and week 12 to evaluate the response to the iTBS treatment.
Neuropsychological function assessment Brief Assessment of Cognition in Affective Disorders (BACA) Investigators will adopt the BACA to evaluate objective cognitive functioning in patients with mood disorders. This instrument consists of seven subtests, including Verbal Memory (List Learning), Working Memory (Digit Sequencing), Processing Speed (Verbal Fluency; Token Motor Task; Symbol Coding), Reasoning and Problem Solving (Tower of London \[TOL\]), and tests of affective interference (emotional distractibility and affective memory) and emotional disinhibition, which are then summed up as affective composite scores. This assessment takes approximately 45 minutes.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Bipolar II Disorder, Most Recent Episode Major Depressive
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
one experimental and one sham group
Primary Study Purpose
TREATMENT
Blinding Strategy
SINGLE
Participants
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
experimental (iTBS group)
device: Magstim Rapid2 Stimulator
Group Type
EXPERIMENTAL
repetitive transcranial magnetic stimulation (rTMS)
Intervention Type
DEVICE
Investigators adopted the iTBS protocol which follows the standard TBS protocols, with 3-pulse 50-Hz bursts given every 200 ms (at 5 Hz) and an intensity of 80% motor threshold. In each session, a 2-s train of bursts will be repeated every 10 s for a total of 570 s (1800 pulses) to the left dorsolateral prefrontal cortex (DLPFC). TBS sessions will be scheduled daily in a 5-day sequence, for a total of 10 sessions in 2 weeks.
sham group
device shame Magstim Rapid2 Stimulator
Group Type
SHAM_COMPARATOR
sham repetitive transcranial magnetic stimulation (rTMS)
Intervention Type
DEVICE
no stimulation, Sham TBS sessions will be scheduled daily in a 5-day sequence, for a total of 10 sessions in 2 weeks.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
repetitive transcranial magnetic stimulation (rTMS)
Investigators adopted the iTBS protocol which follows the standard TBS protocols, with 3-pulse 50-Hz bursts given every 200 ms (at 5 Hz) and an intensity of 80% motor threshold. In each session, a 2-s train of bursts will be repeated every 10 s for a total of 570 s (1800 pulses) to the left dorsolateral prefrontal cortex (DLPFC). TBS sessions will be scheduled daily in a 5-day sequence, for a total of 10 sessions in 2 weeks.
Intervention Type
DEVICE
sham repetitive transcranial magnetic stimulation (rTMS)
no stimulation, Sham TBS sessions will be scheduled daily in a 5-day sequence, for a total of 10 sessions in 2 weeks.
Intervention Type
DEVICE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. The Chinese Version of Modified Schedule of Affective Disorder and Schizophrenia-Life Time (SADS-L) and DSM-IV-TR will be conducted for confirmation of the diagnosis of BD-II.
2. Aged 20-65.
3. HDRS and YMRS will be used to evaluate severity of mood symptoms. Only patients in deressive state (HDRS≧18) will be recruited.
2. Aged 20-65.
3. HDRS and YMRS will be used to evaluate severity of mood symptoms. Only patients in deressive state (HDRS≧18) will be recruited.
Exclusion Criteria
1. Any DSM-IV-TR Axis I diagnosis, including organic mental disorders, substance use disorder, and other major and minor mental illnesses other than BD-II.
2. Any significant medical illness.
3. Any neurological disorders.
4. Any poorly controlled physical illness that might influence the interview and study results.
5. Any form of metal implants.
6. Any history of seizures, or medications known to lower seizure threshold.
7. History of exposure to TMS or electroconvulsive therapy.
2. Any significant medical illness.
3. Any neurological disorders.
4. Any poorly controlled physical illness that might influence the interview and study results.
5. Any form of metal implants.
6. Any history of seizures, or medications known to lower seizure threshold.
7. History of exposure to TMS or electroconvulsive therapy.
Minimum Eligible Age
20 Years
Maximum Eligible Age
65 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Kaohsiung Veterans General Hospital.
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Sheng Yu Lee
Attending physician, Department of Psychiatry, Kaohsiung Veterans General Hospital
Responsibility Role
PRINCIPAL_INVESTIGATOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
KaohsiungVGH
Kaohsiung City, , Taiwan
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
Taiwan
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Angst J, Gamma A, Benazzi F, Ajdacic V, Eich D, Rossler W. Toward a re-definition of subthreshold bipolarity: epidemiology and proposed criteria for bipolar-II, minor bipolar disorders and hypomania. J Affect Disord. 2003 Jan;73(1-2):133-46. doi: 10.1016/s0165-0327(02)00322-1.
Reference Type
BACKGROUND
Benazzi F, Akiskal HS. Refining the evaluation of bipolar II: beyond the strict SCID-CV guidelines for hypomania. J Affect Disord. 2003 Jan;73(1-2):33-8. doi: 10.1016/s0165-0327(02)00327-0.
Reference Type
BACKGROUND
Akiskal HS, Pinto O. The evolving bipolar spectrum. Prototypes I, II, III, and IV. Psychiatr Clin North Am. 1999 Sep;22(3):517-34, vii. doi: 10.1016/s0193-953x(05)70093-9.
Reference Type
BACKGROUND
Phillips ML, Kupfer DJ. Bipolar disorder diagnosis: challenges and future directions. Lancet. 2013 May 11;381(9878):1663-71. doi: 10.1016/S0140-6736(13)60989-7.
Reference Type
BACKGROUND
Vieta E, Berk M, Schulze TG, Carvalho AF, Suppes T, Calabrese JR, Gao K, Miskowiak KW, Grande I. Bipolar disorders. Nat Rev Dis Primers. 2018 Mar 8;4:18008. doi: 10.1038/nrdp.2018.8.
Reference Type
BACKGROUND
Carvalho AF, Firth J, Vieta E. Bipolar Disorder. N Engl J Med. 2020 Jul 2;383(1):58-66. doi: 10.1056/NEJMra1906193. No abstract available.
Reference Type
BACKGROUND
Judd LL, Akiskal HS. Depressive episodes and symptoms dominate the longitudinal course of bipolar disorder. Curr Psychiatry Rep. 2003 Dec;5(6):417-8. doi: 10.1007/s11920-003-0077-2. No abstract available.
Reference Type
BACKGROUND
Mosolov S, Ushkalova A, Kostukova E, Shafarenko A, Alfimov P, Kostyukova A, Angst J. Bipolar II disorder in patients with a current diagnosis of recurrent depression. Bipolar Disord. 2014 Jun;16(4):389-99. doi: 10.1111/bdi.12192. Epub 2014 Mar 1.
Reference Type
BACKGROUND
Earley W, Burgess MV, Rekeda L, Dickinson R, Szatmari B, Nemeth G, McIntyre RS, Sachs GS, Yatham LN. Cariprazine Treatment of Bipolar Depression: A Randomized Double-Blind Placebo-Controlled Phase 3 Study. Am J Psychiatry. 2019 Jun 1;176(6):439-448. doi: 10.1176/appi.ajp.2018.18070824. Epub 2019 Mar 8.
Reference Type
BACKGROUND
Nierenberg AA, McIntyre RS, Sachs GS. Improving outcomes in patients with bipolar depression: a comprehensive review. J Clin Psychiatry. 2015 Mar;76(3):e10. doi: 10.4088/JCP.13091ip1.
Reference Type
BACKGROUND
El-Mallakh RS, Vohringer PA, Ostacher MM, Baldassano CF, Holtzman NS, Whitham EA, Thommi SB, Goodwin FK, Ghaemi SN. Antidepressants worsen rapid-cycling course in bipolar depression: A STEP-BD randomized clinical trial. J Affect Disord. 2015 Sep 15;184:318-21. doi: 10.1016/j.jad.2015.04.054. Epub 2015 Jun 10.
Reference Type
BACKGROUND
Rossini PM, Rossi S. Transcranial magnetic stimulation: diagnostic, therapeutic, and research potential. Neurology. 2007 Feb 13;68(7):484-8. doi: 10.1212/01.wnl.0000250268.13789.b2.
Reference Type
BACKGROUND
Hett D, Marwaha S. Repetitive Transcranial Magnetic Stimulation in the Treatment of Bipolar Disorder. Ther Adv Psychopharmacol. 2020 Nov 18;10:2045125320973790. doi: 10.1177/2045125320973790. eCollection 2020.
Reference Type
BACKGROUND
Goldwaser EL, Daddario K, Aaronson ST. A retrospective analysis of bipolar depression treated with transcranial magnetic stimulation. Brain Behav. 2020 Dec;10(12):e01805. doi: 10.1002/brb3.1805. Epub 2020 Nov 10.
Reference Type
BACKGROUND
McGirr A, Karmani S, Arsappa R, Berlim MT, Thirthalli J, Muralidharan K, Yatham LN. Clinical efficacy and safety of repetitive transcranial magnetic stimulation in acute bipolar depression. World Psychiatry. 2016 Feb;15(1):85-6. doi: 10.1002/wps.20300. No abstract available.
Reference Type
BACKGROUND
Daskalakis ZJ. Theta-burst transcranial magnetic stimulation in depression: when less may be more. Brain. 2014 Jul;137(Pt 7):1860-2. doi: 10.1093/brain/awu123. Epub 2014 May 15. No abstract available.
Reference Type
BACKGROUND
Blumberger DM, Vila-Rodriguez F, Thorpe KE, Feffer K, Noda Y, Giacobbe P, Knyahnytska Y, Kennedy SH, Lam RW, Daskalakis ZJ, Downar J. Effectiveness of theta burst versus high-frequency repetitive transcranial magnetic stimulation in patients with depression (THREE-D): a randomised non-inferiority trial. Lancet. 2018 Apr 28;391(10131):1683-1692. doi: 10.1016/S0140-6736(18)30295-2. Epub 2018 Apr 26.
Reference Type
BACKGROUND
Li CT, Cheng CM, Chen MH, Juan CH, Tu PC, Bai YM, Jeng JS, Lin WC, Tsai SJ, Su TP. Antidepressant Efficacy of Prolonged Intermittent Theta Burst Stimulation Monotherapy for Recurrent Depression and Comparison of Methods for Coil Positioning: A Randomized, Double-Blind, Sham-Controlled Study. Biol Psychiatry. 2020 Mar 1;87(5):443-450. doi: 10.1016/j.biopsych.2019.07.031. Epub 2019 Aug 9.
Reference Type
BACKGROUND
Li CT, Chen MH, Juan CH, Huang HH, Chen LF, Hsieh JC, Tu PC, Bai YM, Tsai SJ, Lee YC, Su TP. Efficacy of prefrontal theta-burst stimulation in refractory depression: a randomized sham-controlled study. Brain. 2014 Jul;137(Pt 7):2088-98. doi: 10.1093/brain/awu109. Epub 2014 May 10.
Reference Type
BACKGROUND
Luan D, Zhao MG, Shi YC, Li L, Cao YJ, Feng HX, Zhang ZJ. Mechanisms of repetitive transcranial magnetic stimulation for anti-depression: Evidence from preclinical studies. World J Psychiatry. 2020 Oct 19;10(10):223-233. doi: 10.5498/wjp.v10.i10.223. eCollection 2020 Oct 19.
Reference Type
BACKGROUND
Chen YH, Zhang RG, Xue F, Wang HN, Chen YC, Hu GT, Peng Y, Peng ZW, Tan QR. Quetiapine and repetitive transcranial magnetic stimulation ameliorate depression-like behaviors and up-regulate the proliferation of hippocampal-derived neural stem cells in a rat model of depression: The involvement of the BDNF/ERK signal pathway. Pharmacol Biochem Behav. 2015 Sep;136:39-46. doi: 10.1016/j.pbb.2015.07.005. Epub 2015 Jul 12.
Reference Type
BACKGROUND
Pasquinelli AE. MicroRNAs and their targets: recognition, regulation and an emerging reciprocal relationship. Nat Rev Genet. 2012 Mar 13;13(4):271-82. doi: 10.1038/nrg3162.
Reference Type
BACKGROUND
Saba R, Schratt GM. MicroRNAs in neuronal development, function and dysfunction. Brain Res. 2010 Jun 18;1338:3-13. doi: 10.1016/j.brainres.2010.03.107. Epub 2010 Apr 7.
Reference Type
BACKGROUND
Magill ST, Cambronne XA, Luikart BW, Lioy DT, Leighton BH, Westbrook GL, Mandel G, Goodman RH. microRNA-132 regulates dendritic growth and arborization of newborn neurons in the adult hippocampus. Proc Natl Acad Sci U S A. 2010 Nov 23;107(47):20382-7. doi: 10.1073/pnas.1015691107. Epub 2010 Nov 8.
Reference Type
BACKGROUND
Moreau MP, Bruse SE, David-Rus R, Buyske S, Brzustowicz LM. Altered microRNA expression profiles in postmortem brain samples from individuals with schizophrenia and bipolar disorder. Biol Psychiatry. 2011 Jan 15;69(2):188-93. doi: 10.1016/j.biopsych.2010.09.039.
Reference Type
BACKGROUND
Wang Z, Zhang C, Huang J, Yuan C, Hong W, Chen J, Yu S, Xu L, Gao K, Fang Y. MiRNA-206 and BDNF genes interacted in bipolar I disorder. J Affect Disord. 2014 Jun;162:116-9. doi: 10.1016/j.jad.2014.03.047. Epub 2014 Apr 3.
Reference Type
BACKGROUND
Ha TY. The Role of MicroRNAs in Regulatory T Cells and in the Immune Response. Immune Netw. 2011 Feb;11(1):11-41. doi: 10.4110/in.2011.11.1.11. Epub 2011 Feb 28.
Reference Type
BACKGROUND
Bocchio-Chiavetto L, Maffioletti E, Bettinsoli P, Giovannini C, Bignotti S, Tardito D, Corrada D, Milanesi L, Gennarelli M. Blood microRNA changes in depressed patients during antidepressant treatment. Eur Neuropsychopharmacol. 2013 Jul;23(7):602-11. doi: 10.1016/j.euroneuro.2012.06.013. Epub 2012 Aug 25.
Reference Type
BACKGROUND
Lee SY, Lu RB, Wang LJ, Chang CH, Lu T, Wang TY, Tsai KW. Serum miRNA as a possible biomarker in the diagnosis of bipolar II disorder. Sci Rep. 2020 Jan 24;10(1):1131. doi: 10.1038/s41598-020-58195-0.
Reference Type
BACKGROUND
Soeiro-de-Souza MG, Dias VV, Figueira ML, Forlenza OV, Gattaz WF, Zarate CA Jr, Machado-Vieira R. Translating neurotrophic and cellular plasticity: from pathophysiology to improved therapeutics for bipolar disorder. Acta Psychiatr Scand. 2012 Nov;126(5):332-41. doi: 10.1111/j.1600-0447.2012.01889.x. Epub 2012 Jun 8.
Reference Type
BACKGROUND
Lim CS, Baldessarini RJ, Vieta E, Yucel M, Bora E, Sim K. Longitudinal neuroimaging and neuropsychological changes in bipolar disorder patients: review of the evidence. Neurosci Biobehav Rev. 2013 Mar;37(3):418-35. doi: 10.1016/j.neubiorev.2013.01.003. Epub 2013 Jan 12.
Reference Type
BACKGROUND
Monteggia LM, Barrot M, Powell CM, Berton O, Galanis V, Gemelli T, Meuth S, Nagy A, Greene RW, Nestler EJ. Essential role of brain-derived neurotrophic factor in adult hippocampal function. Proc Natl Acad Sci U S A. 2004 Jul 20;101(29):10827-32. doi: 10.1073/pnas.0402141101. Epub 2004 Jul 12.
Reference Type
BACKGROUND
Cotman CW, Berchtold NC. Exercise: a behavioral intervention to enhance brain health and plasticity. Trends Neurosci. 2002 Jun;25(6):295-301. doi: 10.1016/s0166-2236(02)02143-4.
Reference Type
BACKGROUND
Hofer M, Pagliusi SR, Hohn A, Leibrock J, Barde YA. Regional distribution of brain-derived neurotrophic factor mRNA in the adult mouse brain. EMBO J. 1990 Aug;9(8):2459-64. doi: 10.1002/j.1460-2075.1990.tb07423.x.
Reference Type
BACKGROUND
de Oliveira GS, Cereser KM, Fernandes BS, Kauer-Sant'Anna M, Fries GR, Stertz L, Aguiar B, Pfaffenseller B, Kapczinski F. Decreased brain-derived neurotrophic factor in medicated and drug-free bipolar patients. J Psychiatr Res. 2009 Sep;43(14):1171-4. doi: 10.1016/j.jpsychires.2009.04.002. Epub 2009 May 26.
Reference Type
BACKGROUND
Fernandes BS, Gama CS, Cereser KM, Yatham LN, Fries GR, Colpo G, de Lucena D, Kunz M, Gomes FA, Kapczinski F. Brain-derived neurotrophic factor as a state-marker of mood episodes in bipolar disorders: a systematic review and meta-regression analysis. J Psychiatr Res. 2011 Aug;45(8):995-1004. doi: 10.1016/j.jpsychires.2011.03.002. Epub 2011 May 6.
Reference Type
BACKGROUND
Molendijk ML, Spinhoven P, Polak M, Bus BA, Penninx BW, Elzinga BM. Serum BDNF concentrations as peripheral manifestations of depression: evidence from a systematic review and meta-analyses on 179 associations (N=9484). Mol Psychiatry. 2014 Jul;19(7):791-800. doi: 10.1038/mp.2013.105. Epub 2013 Aug 20.
Reference Type
BACKGROUND
Kauer-Sant'Anna M, Kapczinski F, Andreazza AC, Bond DJ, Lam RW, Young LT, Yatham LN. Brain-derived neurotrophic factor and inflammatory markers in patients with early- vs. late-stage bipolar disorder. Int J Neuropsychopharmacol. 2009 May;12(4):447-58. doi: 10.1017/S1461145708009310. Epub 2008 Sep 4.
Reference Type
BACKGROUND
Cheng LC, Pastrana E, Tavazoie M, Doetsch F. miR-124 regulates adult neurogenesis in the subventricular zone stem cell niche. Nat Neurosci. 2009 Apr;12(4):399-408. doi: 10.1038/nn.2294. Epub 2009 Mar 15.
Reference Type
BACKGROUND
Liu C, Teng ZQ, Santistevan NJ, Szulwach KE, Guo W, Jin P, Zhao X. Epigenetic regulation of miR-184 by MBD1 governs neural stem cell proliferation and differentiation. Cell Stem Cell. 2010 May 7;6(5):433-44. doi: 10.1016/j.stem.2010.02.017.
Reference Type
BACKGROUND
Li B, Jiang Y, Xu Y, Li Y, Li B. Identification of miRNA-7 as a regulator of brain-derived neurotrophic factor/alpha-synuclein axis in atrazine-induced Parkinson's disease by peripheral blood and brain microRNA profiling. Chemosphere. 2019 Oct;233:542-548. doi: 10.1016/j.chemosphere.2019.05.064. Epub 2019 May 23.
Reference Type
BACKGROUND
Gupta N, Jadhav S, Tan KL, Saw G, Mallilankaraman KB, Dheen ST. miR-142-3p Regulates BDNF Expression in Activated Rodent Microglia Through Its Target CAMK2A. Front Cell Neurosci. 2020 May 21;14:132. doi: 10.3389/fncel.2020.00132. eCollection 2020.
Reference Type
BACKGROUND
Lian N, Niu Q, Lei Y, Li X, Li Y, Song X. MiR-221 is involved in depression by regulating Wnt2/CREB/BDNF axis in hippocampal neurons. Cell Cycle. 2018;17(24):2745-2755. doi: 10.1080/15384101.2018.1556060. Epub 2018 Dec 27.
Reference Type
BACKGROUND
Lulli V, Buccarelli M, Ilari R, Castellani G, De Dominicis C, Di Giamberardino A, D Alessandris QG, Giannetti S, Martini M, Stumpo V, Boe A, De Luca G, Biffoni M, Marziali G, Pallini R, Ricci-Vitiani L. Mir-370-3p Impairs Glioblastoma Stem-Like Cell Malignancy Regulating a Complex Interplay between HMGA2/HIF1A and the Oncogenic Long Non-Coding RNA (lncRNA) NEAT1. Int J Mol Sci. 2020 May 20;21(10):3610. doi: 10.3390/ijms21103610.
Reference Type
BACKGROUND
Visitchanakun P, Tangtanatakul P, Trithiphen O, Soonthornchai W, Wongphoom J, Tachaboon S, Srisawat N, Leelahavanichkul A. Plasma miR-370-3P as a Biomarker of Sepsis-Associated Encephalopathy, the Transcriptomic Profiling Analysis of Microrna-Arrays From Mouse Brains. Shock. 2020 Sep;54(3):347-357. doi: 10.1097/SHK.0000000000001473.
Reference Type
BACKGROUND
Yuan H, Mischoulon D, Fava M, Otto MW. Circulating microRNAs as biomarkers for depression: Many candidates, few finalists. J Affect Disord. 2018 Jun;233:68-78. doi: 10.1016/j.jad.2017.06.058. Epub 2017 Jun 27.
Reference Type
BACKGROUND
Rubinsztein JS, Michael A, Paykel ES, Sahakian BJ. Cognitive impairment in remission in bipolar affective disorder. Psychol Med. 2000 Sep;30(5):1025-36. doi: 10.1017/s0033291799002664.
Reference Type
BACKGROUND
Martinez-Aran A, Vieta E, Colom F, Torrent C, Sanchez-Moreno J, Reinares M, Benabarre A, Goikolea JM, Brugue E, Daban C, Salamero M. Cognitive impairment in euthymic bipolar patients: implications for clinical and functional outcome. Bipolar Disord. 2004 Jun;6(3):224-32. doi: 10.1111/j.1399-5618.2004.00111.x.
Reference Type
BACKGROUND
Simonsen C, Sundet K, Vaskinn A, Birkenaes AB, Engh JA, Hansen CF, Jonsdottir H, Ringen PA, Opjordsmoen S, Friis S, Andreassen OA. Neurocognitive profiles in bipolar I and bipolar II disorder: differences in pattern and magnitude of dysfunction. Bipolar Disord. 2008 Mar;10(2):245-55. doi: 10.1111/j.1399-5618.2007.00492.x.
Reference Type
BACKGROUND
Summers M, Papadopoulou K, Bruno S, Cipolotti L, Ron MA. Bipolar I and bipolar II disorder: cognition and emotion processing. Psychol Med. 2006 Dec;36(12):1799-809. doi: 10.1017/S0033291706008804. Epub 2006 Aug 29.
Reference Type
BACKGROUND
Harkavy-Friedman JM, Keilp JG, Grunebaum MF, Sher L, Printz D, Burke AK, Mann JJ, Oquendo M. Are BPI and BPII suicide attempters distinct neuropsychologically? J Affect Disord. 2006 Aug;94(1-3):255-9. doi: 10.1016/j.jad.2006.04.010. Epub 2006 Jun 5.
Reference Type
BACKGROUND
Lee CY, Wang LJ, Lee Y, Hung CF, Huang YC, Lee MI, Lee SY. Differentiating bipolar disorders from unipolar depression by applying the Brief Assessment of Cognition in Affective Disorders. Psychol Med. 2018 Apr;48(6):929-938. doi: 10.1017/S003329171700229X. Epub 2017 Aug 22.
Reference Type
BACKGROUND
Lee SY, Wang LJ, Chang CH, Wu CC, Chen HL, Lin SH, Chu CL, Lu T, Lu RB. Serum DHEA-S concentration correlates with clinical symptoms and neurocognitive function in patients with bipolar II disorder: A case-controlled study. Prog Neuropsychopharmacol Biol Psychiatry. 2017 Mar 6;74:31-35. doi: 10.1016/j.pnpbp.2016.11.006. Epub 2016 Nov 30.
Reference Type
BACKGROUND
Pridmore S, Fernandes Filho JA, Nahas Z, Liberatos C, George MS. Motor threshold in transcranial magnetic stimulation: a comparison of a neurophysiological method and a visualization of movement method. J ECT. 1998 Mar;14(1):25-7.
Reference Type
BACKGROUND
Keefe RS, Fox KH, Davis VG, Kennel C, Walker TM, Burdick KE, Harvey PD. The Brief Assessment of Cognition In Affective Disorders (BAC-A):performance of patients with bipolar depression and healthy controls. J Affect Disord. 2014 Sep;166:86-92. doi: 10.1016/j.jad.2014.05.002. Epub 2014 May 11.
Reference Type
BACKGROUND
Lee CY, Lee SY, Huang YC, Hung CF, Lee Y, Lee MI, Wang LJ. The Chinese version of the Brief Assessment of Cognition in Affective Disorders: normative data of a Mandarin-speaking population. Clin Neuropsychol. 2018 Jan-Dec;32(sup1):1-14. doi: 10.1080/13854046.2017.1400108. Epub 2017 Nov 6.
Reference Type
BACKGROUND
Wang LJ, Lin PY, Lee Y, Huang YC, Hsu ST, Hung CF, Chen CK, Chen YC, Wang YL, Tsai MC. Validation of the Chinese version of Brief Assessment of Cognition in Schizophrenia. Neuropsychiatr Dis Treat. 2016 Oct 31;12:2819-2826. doi: 10.2147/NDT.S118110. eCollection 2016.
Reference Type
BACKGROUND
Li Z, Wang Z, Zhang C, Chen J, Su Y, Huang J, Yi Z, Yuan C, Hong W, Wang Y, Wu Z, Hu Y, Cao L, Peng D, Guan Y, Zou Y, Yu S, Cui D, Fang Y. Reduced ENA78 levels as novel biomarker for major depressive disorder and venlafaxine efficiency: Result from a prospective longitudinal study. Psychoneuroendocrinology. 2017 Jul;81:113-121. doi: 10.1016/j.psyneuen.2017.03.015. Epub 2017 Mar 18.
Reference Type
BACKGROUND
Zeger SL, Liang KY, Albert PS. Models for longitudinal data: a generalized estimating equation approach. Biometrics. 1988 Dec;44(4):1049-60.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
21-CT3-23(210303-1)
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Transcranial Magnetic Stimulation vs Theta Burst Stimulation in Major Depressive Disorder
NCT04497350
UNKNOWN
NA
Right-sided 1-Hz Repetitive Transcranial Magnetic Stimulation (rTMS) Versus Left-sided Intermittent Theta Burst Stimulation (iTBS) in Patients With Depression
NCT07026461
RECRUITING
PHASE4
Theta-Burst Stimulation in Major Depressive Episodes With Mixed Characteristics.
NCT04123301
UNKNOWN
NA
iTBS Study for Depression (Randomized)
NCT03745768
COMPLETED
NA
Dorsomedial Prefrontal Neuromodulation in Treatment-resistant Depression
NCT05422417
RECRUITING
NA
Evaluation of Theta-burst Stimulation Efficacy, Safety and Tolerability in Major Depressive Episodes of Bipolar I Disorder
NCT05501626
UNKNOWN
NA
Accelerated Intermittent Theta-Burst Stimulation (aiTBS) in Treatment-Resistant Depression of Bipolar II Disorder
NCT05849402
RECRUITING
NA
Theta-Burst Stimulation for Bipolar Depression
NCT06370988
RECRUITING
NA
Accelerated Intermittent Theta Burst Stimulation for Depressed Patients During the Covid-19 Pandemic
NCT04935489
COMPLETED
NA
Effects of Theta Burst Stimulation on the Brain, Behavior, and Clinical Symptoms in Adults With Bipolar Disorder
NCT04696471
COMPLETED
NA
Intermittent Theta-burst Stimulation for Major Depression: an Intensity-response Study
NCT06392867
RECRUITING
NA
Efficacy of rTMS in Bipolar Depression
NCT02749006
TERMINATED
NA
Neuronavigation rTMS to Improve Depressive Episodes of Bipolar Disorder in Adolescent
NCT05929183
COMPLETED
NA
Practical Application of Accelerated iTBS for MDD
NCT06113575
COMPLETED
NA
Efficacy of Intermittent ThetaBurst Stimulation Compared to 10 Hz Stimulation on Dorsolateral Prefrontal Cortex in Treatment Resistant Major Depressive Disorder: a Double-blind Randomized Study
NCT02376491
COMPLETED
NA
Cross-validating the iTBS-induced Hemodynamic Response From fNIRS and fMRI: a Concurrent iTBS-fMRI-fNIRS Study
NCT06902571
RECRUITING
iTBS in Bipolar I Depression
NCT05375214
COMPLETED
NA
Safety and Efficacy Study of Deep Transcranial Magnetic Stimulation in Bipolar Depression
NCT01566591
UNKNOWN
NA
Efficacy and Biomarkers of Response of TBS in Treatment Resistant Depression
NCT04998773
RECRUITING
NA
iTBS rTMS in Mild Cognitive Impairment
NCT05327257
COMPLETED
NA
Task-State-Based Temporal Interference Stimulation (TI) to Improve Depression in Patients With Bipolar Disorder
NCT06516991
COMPLETED
NA
iTBS Study for Depression in Patients With Multiple Sclerosis
NCT04524039
UNKNOWN
NA
Neural Mechanisms of Intermittent Theta Burst Stimulation in the Core Depression Network
NCT05224206
RECRUITING
NA
Intermittent Theta Burst Stimulation on Anhedonia in Depression
NCT06552026
COMPLETED
NA
The Antidepressant Effect of Intermittent Theta Burst Stimulation (iTBS)
NCT05516095
COMPLETED
NA